Compare TPVG & RXST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TPVG | RXST |
|---|---|---|
| Founded | 2013 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 224.9M | 232.2M |
| IPO Year | 2013 | 2021 |
| Metric | TPVG | RXST |
|---|---|---|
| Price | $5.49 | $6.48 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 5 | 10 |
| Target Price | $5.90 | ★ $9.78 |
| AVG Volume (30 Days) | 211.7K | ★ 885.9K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | ★ 17.66% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.43 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $7.67 | N/A |
| Revenue Next Year | N/A | $10.06 |
| P/E Ratio | $12.67 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.40 | $4.48 |
| 52 Week High | $6.95 | $13.22 |
| Indicator | TPVG | RXST |
|---|---|---|
| Relative Strength Index (RSI) | 70.88 | 55.99 |
| Support Level | $5.43 | $5.26 |
| Resistance Level | $5.66 | $6.53 |
| Average True Range (ATR) | 0.16 | 0.37 |
| MACD | 0.10 | 0.04 |
| Stochastic Oscillator | 100.00 | 55.87 |
TriplePoint Venture Growth BDC Corp is a closed-end, non-diversified management investment company. Its investment objective is to maximize its total return to stockholders in the form of current income and, to a lesser extent, capital appreciation. The fund focuses on companies operating in the fields of biofuels, business applications software, wireless communications equipment, e-commerce, clothing and accessories, conferencing equipment and services, personal goods, financial institutions and services, entertainment, mixed retailing, and healthcare services. Geographically, all the firm's operations are located across the United States.
RxSight Inc is a commercial-stage medical technology company dedicated to improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture, and sale of light adjustable lenses and related capital equipment.